Literature DB >> 19149564

Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets.

Maria Assunta Potenza1, Sara Gagliardi, Carmela Nacci, Maria Rosaria Carratu', Monica Montagnani.   

Abstract

Micro- and macrovascular complications are major causes of disability and death in patients with diabetes mellitus. Functional impairment of endothelial activity precedes the development of morphological alterations during the progression of diabetes. This endothelial dysfunction results from reduced bioavailability of the vasodilator nitric oxide (NO), mainly due to accelerated NO degradation by reactive oxygen species (ROS). Although hyperglycemia, insulin resistance, hyperinsulinemia and dyslipidemia independently contribute to endothelial dysfunction via several distinct mechanisms, increased oxidative stress seems to be the first alteration triggering several others. Mechanisms proposed to explain glucose- and lipid-induced vascular alterations in diabetes include accelerated formation of advanced glycation end-products (AGEs), protein kinase C activation, inflammatory signaling and oxidative stress. Insulin resistance with impaired PI 3-kinase effects decreases insulin mediated production of NO and reduces vasodilation, capillary recruitment and antioxidant properties of endothelium. Compensatory hyperinsulinemia enhances activation of intact MAP-kinase pathways and contributes to pro-atherogenic events by increasing secretion of endothelin-1 (ET-1), stimulating expression of adhesion molecules such as VCAM-1 and E-selectin, and inducing production of ROS. Conventional therapies to reduce hyperglycemia, dyslipidemia and insulin resistance may effectively improve endothelial function and delay the onset of vascular complications. Novel therapeutic approaches designed to inhibit AGEs formation, reduce PKC activation, decrease inflammatory signals and restore the ox/redox balance of endothelium may be predicted to ameliorate vascular function in diabetic state. This review summarizes the current knowledge on the most important mechanisms involved in endothelial dysfunction during diabetes. In addition, novel therapeutic strategies that may result from recently identified targets are also described.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19149564     DOI: 10.2174/092986709787002853

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  91 in total

1.  Diabetic retinopathy and endothelial dysfunction in patients with type 2 diabetes mellitus.

Authors:  Jae-Seung Yun; Seung-Hyun Ko; Ji-Hoon Kim; Keon-Woong Moon; Kun-Woong Moon; Yong-Moon Park; Ki-Dong Yoo; Yu-Bae Ahn
Journal:  Diabetes Metab J       Date:  2013-08-14       Impact factor: 5.376

2.  Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature.

Authors:  Maria A Potenza; Sara Gagliardi; Leonarda De Benedictis; Addolorata Zigrino; Edy Tiravanti; Giuseppe Colantuono; Antonio Federici; Loredana Lorusso; Vincenzo Benagiano; Michael J Quon; Monica Montagnani
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-16       Impact factor: 4.310

3.  The effect of type-2-diabetes-related vascular endothelial dysfunction on skin physiology and activities of daily living.

Authors:  Jerrold Scott Petrofsky
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

Review 4.  Biological activities of receptor-interacting protein 140 in adipocytes and metabolic diseases.

Authors:  Ping-Chih Ho; Li-Na Wei
Journal:  Curr Diabetes Rev       Date:  2012-11

5.  Endothelial PGC-1α mediates vascular dysfunction in diabetes.

Authors:  Naoki Sawada; Aihua Jiang; Fumihiko Takizawa; Adeel Safdar; Andre Manika; Yevgenia Tesmenitsky; Kyu-Tae Kang; Joyce Bischoff; Hermann Kalwa; Juliano L Sartoretto; Yasutomi Kamei; Laura E Benjamin; Hirotaka Watada; Yoshihiro Ogawa; Yasutomi Higashikuni; Chase W Kessinger; Farouc A Jaffer; Thomas Michel; Masataka Sata; Kevin Croce; Rica Tanaka; Zolt Arany
Journal:  Cell Metab       Date:  2014-02-04       Impact factor: 27.287

Review 6.  Induced Pluripotent Stem Cell-Derived Endothelial Cells in Insulin Resistance and Metabolic Syndrome.

Authors:  Ivan Carcamo-Orive; Ngan F Huang; Thomas Quertermous; Joshua W Knowles
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-07-20       Impact factor: 8.311

7.  Nanomedicines for Endothelial Disorders.

Authors:  Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer
Journal:  Nano Today       Date:  2015-12-01       Impact factor: 20.722

8.  Molecular mechanisms of hyperglycemia and cardiovascular-related events in critically ill patients: rationale for the clinical benefits of insulin therapy.

Authors:  Samer Ellahham
Journal:  Clin Epidemiol       Date:  2010-12-12       Impact factor: 4.790

9.  Simvastatin, atorvastatin, and pravastatin equally improve the hemodynamic status of diabetic rats.

Authors:  María J Crespo; José Quidgley
Journal:  World J Diabetes       Date:  2015-08-25

10.  Aminoguanidine inhibits aortic hydrogen peroxide production, VSMC NOX activity and hypercontractility in diabetic mice.

Authors:  Jeong-Ho Oak; Ji-Youn Youn; Hua Cai
Journal:  Cardiovasc Diabetol       Date:  2009-12-30       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.